Vibgyor Drugs Profile
Key Indicators
- Authorised Capital ₹ 5.00 Cr
as on 15-12-2024
- Paid Up Capital ₹ 5.00 Cr
as on 15-12-2024
- Company Age 15 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 1.20 Cr
as on 15-12-2024
- Satisfied Charges ₹ 4.95 Cr
as on 15-12-2024
- Revenue 215.18%
(FY 2022)
- Profit 159.50%
(FY 2022)
- Ebitda -5.80%
(FY 2022)
- Net Worth 1.24%
(FY 2022)
- Total Assets 14.23%
(FY 2022)
About Vibgyor Drugs
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 5.00 Cr and a paid-up capital of Rs 5.00 Cr.
The company currently has active open charges totaling ₹1.20 Cr. The company has closed loans amounting to ₹4.95 Cr, as per Ministry of Corporate Affairs (MCA) records.
Venkata Koganti and Geetha Koganti serve as directors at the Company.
- CIN/LLPIN
U24100TG2009PTC063120
- Company No.
063120
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
20 Mar 2009
- Date of AGM
29 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Company Details
- Location
Nizamabad, Telangana, India
- Telephone
- Email Address
- Website
- Social Media-
Who are the key members and board of directors at Vibgyor Drugs?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Venkata Koganti  | Managing Director | 05-Dec-2014 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Geetha Koganti | Director | 28-Nov-2015 | Current |
Financial Performance and Corporate Structure Insights of Vibgyor Drugs.
Vibgyor Drugs Private Limited, for the financial year ended 2022, experienced significant growth in revenue, with a 215.18% increase. The company also saw a substantial improvement in profitability, with a 159.5% increase in profit. The company's net worth moved up by a moderate rise of 1.24%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Vibgyor Drugs?
In 2022, Vibgyor Drugs had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
In-Tech Industries LimitedActive 16 years 2 monthsVenkata Koganti and Geetha Koganti are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Syndicate Bank Creation Date: 12 Dec 2018 | ₹1.20 Cr | Open |
Syndicate Bank Creation Date: 24 Dec 2014 | ₹4.95 Cr | Satisfied |
How Many Employees Work at Vibgyor Drugs?
Vibgyor Drugs has a workforce of 15 employees as of Apr 06, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Vibgyor Drugs, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Vibgyor Drugs's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
